Company / Profit Margin
Taysha Gene Therapies, Inc. Profit Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-1115.3%
FY2025
5-year range
-6975.3% / -722.1%
FY2022-FY2025
Trend
-54.5%
vs FY2024
Sector context
#133 of 146
Health Care
What the data says
Among 146 Health Care companies, Taysha Gene Therapies, Inc. is in the bottom 9% for profit margin. Improved from -6635.3% to -1115.3% over the past 2 years.
Based on SEC 10-K filings.
-1115.3% in FY2025 with a 3-year CAGR of +5860.1%.
Improved from -6635.3% to -1115.3% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +5860.1pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 146This company -1115.3% Sector average -796.3%
▼
-40.1% below sector average
Key checks
Key Insights
- In FY2025, profit margin decreased 54.5% year-over-year.
- Currently 319.0pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -1.03 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -1115.3% | -54.5% |
| FY2024 | -722.1% | +89.1% |
| FY2023 | -6635.3% | +4.9% |
| FY2022 | -6975.3% | - |
| FY2021 | - | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026